Sophia Genetics SA income statement

In fiscal 2025, Sophia Genetics SA reported revenue of $77.3m, up 18.6% on the year before, operating income of −$70.9m (a -91.8% margin) and net income of −$79.0m, or −$1.17 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Sophia Genetics SA: income statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	25	28	40	48	62	65	77
Cost of revenue	8	11	15	16	19	21	25
Gross profit	18	18	25	31	43	44	52
Research and development	15	19	27	35	37	34	34
General and administrative	3	2	5	7	—	—	—
Operating income	—	−37	−71	−88	−75	−67	−71
Interest expense	1	1	1	1	1	2	5
Income before tax	−34	−41	−74	−88	−78	−61	−77
Income tax	0	−2	0	−0	0	1	2
Net income	−34	−39	−74	−87	−79	−62	−79
Diluted EPS	—	−$0.93	−$1.33	−$1.36	−$1.22	−$0.95	−$1.17
Diluted shares (average)	—	42m	55m	64m	65m	66m	68m
EBITDA	—	−35	−68	−82	−66	−58	−61

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: OPRX vs SOPH CCLD vs SOPH AMWL vs SOPH HCTI vs SOPH

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Sophia Genetics SA's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sophia Genetics SA.